Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1995-06-06
2001-02-20
Kunz, Gary L. (Department: 1646)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S252300, C435S252330, C435S255100, C435S320100, C435S325000, C435S070200, C530S350000, C530S399000, C536S023500
Reexamination Certificate
active
06190880
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a series of novel recombinant heterodimeric proteins useful in the field of treating bone defects, healing bone injury and in wound healing in general. The invention also relates to methods for obtaining these heterodimers, methods for producing them by recombinant genetic engineering techniques, and compositions containing them.
BACKGROUND OF THE INVENTION
In recent years, protein factors which are characterized by bone or cartilage growth inducing properties have been isolated and identified. See, e.g., U.S. Pat. No. 5,013,649, PCT published application WO90/11366; PCT published application WO91/05802 and the variety of references cited therein. See, also, PCT/US90/05903 which discloses a protein sequence termed OP-1, which is substantially similar to human BMP-7, and has been reported to have osteogenic activity.
A family of individual bone morphogenetic proteins (BMPs), termed BMP-2 through BMP-9 have been isolated and identified. Incorporated by reference for the purposes of providing disclosure of these proteins and methods of producing them are co-owned, co-pending U.S. patent application Ser. No. 721,847 and the related applications recited in its preamble. Of particular interest, are the proteins termed BMP-2 and BMP-4, disclosed in the above-referenced application; BMP-7, disclosed in Ser. No. 438,919, now U.S. Pat. No. 5,191,905; BMP-5, disclosed in Ser. No. 370,547 now U.S. Pat. No. 5,106,748 and Ser. No. 356,033, now abandoned; and BMP-6, disclosed in Ser. No. 370,544 now abandoned and Ser. No. 347,559 now abandoned; and BMP-8, disclosed in Ser. No. 525,357 now abandoned. Additional members of the BMP family include BMP-1, disclosed in Ser. No. 655,578; BMP-9, disclosed in Ser. No. 720,590 now abandoned; and BMP-3, disclosed in Ser. No. 179,197 now abandoned in favor of Ser. No. 692,565 now U.S. Pat. No. 5,116,738 and PCT publication 89/01464. These applications are incorporated herein by reference for disclosure of these BMPs.
There remains a need in the art for other proteins and compositions useful in the fields of bone and wound healing.
SUMMARY OF THE INVENTION
In one aspect, the invention provides a method for producing a recombinant heterodimeric protein having bone stimulating activity comprising culturing a selected host cell containing a polynucleotide sequence encoding a first selected BMP or fragment thereof and a polynucleotide sequence encoding a second selected BMP or fragment thereof. The resulting co-expressed, biologically active heterodimer is isolated from the culture medium.
According to one embodiment of this invention, the host cell may be co-transfected with one or more vectors containing coding sequences for one or more BMPs. Each BMP polynucleotide sequence may be present on the same vector or on individual vectors transfected into the cell. Alternatively, the BMPs or their fragments may be incorporated into a chromosome of the host cell. Additionally, a single transcription unit may encode single copy of two genes encoding a different BMP.
According to another embodiment of this invention, the selected host cell containing the two polypeptide encoding sequences is a hybrid cell line obtained by fusing two selected, stable host cells, each host cell transfected with, and capable of stably expressing, a polynucleotide sequence encoding a selected first or second BMP or fragment thereof.
In another aspect of the present invention, therefore, there are provided recombinant heterodimeric proteins comprising a protein or fragment of a first BMP in association with a protein or fragment of a second BMP. The heterodimer may be characterized by bone stimulating activity. The heterodimers may comprise a protein or fragment of BMP-2 associated with a protein or fragment of either BMP-5, BMP-6, BMP-7 or BMP-8; or a protein or fragment of BMP-4 associated with a protein or fragment of either BMP-5, BMP-6, BMP-7 or BMP-8. In further embodiments the heterodimers may comprise a protein or fragment of BMP-2 associated with a protein or fragment of either BMP-1, BMP-3 or BMP-4. BMP-4 may also form a heterodimer in association with BMP-1, BMP-2 or a fragment thereof. Still further embodiments may comprise heterodimers involving combinations of BMP-5, BMP-6, BMP-7 and BMP-8. For example, the heterodimers may comprise BMP-5 associated with BMP-6, BMP-7 or BMP-8; BMP-6 associated with BMP-7 or BMP-8; or BMP-7 associated with BMP-8. These heterodimers may be produced by co-expressing each protein in a selected host cell and isolating the heterodimer from the culture medium.
As a further aspect of this invention a cell line is provided which comprises a first polynucleotide sequence encoding a first BMP or fragment thereof and a second polynucleotide sequence encoding a second BMP or fragment thereof, the sequences being under control of one or more suitable expression regulatory systems capable of co-expressing the BMPs as a heterodimer. The cell line may be transfected with one or more than one polynucleotide molecule. Alternatively, the cell line may be a hybrid cell line created by cell fusion as described above.
Another aspect of the invention is a polynucleotide molecule or plasmid vector comprising a polynucleotide sequence encoding a first selected BMP or fragment thereof and a polynucleotide sequence encoding a second selected BMP or fragment thereof. The sequences are under the control at least one suitable regulatory sequence capable of directing co-expression of each protein or fragment. The molecule may contain a single transcription unit containing a copy of both genes, or more than one transcription unit, each containing a copy of a single gene.
As still another aspect of this invention there is provided a method for producing a recombinant dimeric or heterodimeric protein having bone stimulating activity in a prokaryotic cell comprising culturing a selected host cell containing a polynucleotide sequence encoding a first selected BMP or fragment thereof; culturing a second selected host cell containing a polynucleotide sequence encoding a second selected BMP or fragment thereof; isolating monomeric forms of each BMP protein from the culture medium and co-assembling a monomer of the first protein with a monomer of the second protein. The first protein and the second protein may be the same or different BMPs. The resulting biologically active dimer or heterodimer is thereafter isolated from the mixture. Preferred cells are
E. coli.
Thus, as further aspects of this invention recombinant BMP dimers or heterodimers produced in eukaryotic cells are provided, as well as suitable vectors or plasmids, and selected transformed cells useful in such a production method.
Other aspects and advantages of the present invention are described further in the following detailed description of preferred embodiments of the present invention.
REFERENCES:
patent: 4294753 (1981-10-01), Urist
patent: 4434094 (1984-02-01), Seyedin et al.
patent: 4455256 (1984-06-01), Urist
patent: 4563350 (1986-01-01), Nathan
patent: 4608199 (1986-08-01), Caplan et al.
patent: 4627982 (1986-12-01), Seyedin et al.
patent: 4681763 (1987-07-01), Nathanson
patent: 4737578 (1988-04-01), Evans
patent: 4761471 (1988-08-01), Urist
patent: 4769328 (1988-09-01), Murray et al.
patent: 4774228 (1988-09-01), Seyedin
patent: 4774322 (1988-09-01), Seyedin
patent: 4789732 (1988-12-01), Urist
patent: 4798885 (1989-01-01), Mason
patent: 4804744 (1989-02-01), Sen
patent: 4810691 (1989-03-01), Seyedin
patent: 4843063 (1989-06-01), Seyedin
patent: 4886747 (1989-12-01), Derynck
patent: 4908204 (1990-03-01), Robinson et al.
patent: 4968590 (1990-11-01), Kuberasampath et al.
patent: 4992274 (1991-02-01), Robinson et al.
patent: 5011691 (1991-04-01), Oppermann
patent: 5106626 (1992-04-01), Parsons et al.
patent: 5106748 (1992-04-01), Wozney et al.
patent: 5108753 (1992-04-01), Kuberasampath
patent: 5141905 (1992-08-01), Rosen et al.
patent: 5166058 (1992-11-01), Wang et al.
patent: 5187076 (1993-02-01), Wozney et al.
patent: 5187263 (1993-02-01), Murray
Israel David
Wolfman Neil M.
Genetics Institute
Gucker Stephen
Kunz Gary L.
LandOfFree
Recombinant bone morphogenetic protein heterodimers,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant bone morphogenetic protein heterodimers,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant bone morphogenetic protein heterodimers,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2603735